Abstract: Disclosed herein are fusion proteins having a first domain that activates an antigen-presenting cell (APC) (e.g., a dendritic cell) by binding to an activation receptor of the APC, and a second domain that activates an immune effector cell (e.g., a T cell) by targeting a co-stimulatory signaling pathway of the immune effector cell, as well as polynucleotides that encode such fusion proteins. Disclosed herein are also genetically engineered immune effector cells expressing such fusion protein, methods of their production, and their uses in treatment of diseases such as cancers.

Abstract: Disclosed are compositions and methods comprising the administration of pulsed dendritic cells and an immunoregulator molecule inhibitor for the treatment of cancer.

Abstract: In accordance with the present invention, CHO cells expressing a recombinant polypeptide of interest are grown in media where the amino acids, vitamins, phosphate, lipids and/or antioxidant optimization is utilized to manipulate and/or control the protein quality attributes of the polypeptides. Polypeptides expressed in accordance with the present invention may be advantageously used in the preparation of pharmaceutical compositions.

Abstract: The present disclosure provides isolated binding molecules that bind to and blocks PD-L1, vectors comprising a nucleic acid molecules encoding an amino acid sequence of the binding molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease requiring stimulation of immune responses including cancer.

Abstract: The invention provides human AML-specific binding compounds that are able to bind a cell surface component of AML cells. Therapeutic uses of binding compounds against AML are also provided.

Abstract: Compositions and methods are provided for loading cargoes onto red blood cells. Provided herein are novel antibodies, fragments, fusion proteins and other conjugates which specifically bind red blood cells via RHCE or Band 3.

Abstract: This invention relates to agents that bind human Siglecs having inhibitory activity in immune cells, and that neutralize the inhibitory activity of such Siglec. Such agents can be used for the treatment of cancers or infectious disease.

Abstract: The present application relates to neutralizing antibodies or antigen-binding fragments thereof against betacoronaviruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), to nucleic acid(s) encoding such neutralizing antibodies or antigen-binding fragments thereof, and to mixture and compositions comprising such antibodies, antigen-binding fragments or nucleic acids. Such neutralizing antibodies or antigen-binding fragments thereof are able to block betacoronavirus entry into cells and/or to induce complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) and/or antibody-dependent cellular phagocytosis (ADCP) against betacoronavirus-infected cells. Methods and uses of the antibodies, antigen-binding fragments thereof, nucleic acid(s) or compositions, including therapeutic, diagnostic, and preventative methods and uses for betacoronavirus infections and related diseases such as COVID-19, are also described.

Abstract: A prodrugged antibody has a blocking moiety attached to a Cys on its heavy or light chain via a linker having a cleavable moiety. The blocking moiety inhibits binding of the antibody to its antigen. Cleavage of the cleavable moiety releases the blocking moiety and restores ability of the antibody to bind to its antigen.

Abstract: Provided are methods of clinical treatment of follicular lymphoma (for example, relapsed and/or refractory follicular lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimens of rituximab and lenalidomide.

Abstract: Peptides that form adhesive bonds, even in aqueous and/or saline environments, are disclosed. When aggregated, the peptides may be used in methods for producing hydrogels and/or adhesive materials. Synthetic peptide analogs are provided that are designed based on protein sequences found in barnacle adhesive, and may optionally be augmented with chemistry from other organisms that secrete proteins that adhere to substrates. The peptides may be used, for example, in biomedical and aqueous applications. Methods of using the aggregated peptides as adhesives are also provided.

Abstract: The present invention relates to antibodies that specifically bind CD3. The present invention relates to antibodies that specifically bind PSMA. The present invention relates to antibodies that specifically bind CD3 and PSMA. The present invention relates to antibodies that specifically bind IL1RAP. The present invention relates to antibodies that specifically bind CD33. The present invention relates to antibodies that specifically bind CD3 and IL1RAP. The present invention relates to antibodies that specifically bind CD3 and CD33. The present invention relates to antibodies that specifically bind TMEFF2. The present invention relates to antibodies that specifically bind CD3 and TMEFF2. The present invention relates to fragments of the antibodies, polynucleotides encoding the antibodies or fragments thereof, and methods of making and using the same.

Abstract: Provided herein are methods for alleviating symptoms in a subject having Rett syndrome, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D).

Abstract: The present invention relates to anti-human PD-L2 antibodies, or the antigen binding parts thereof, which specifically bind human PD-L2 such that PD-L2 binding to PD-1 is blocked, wherein preferably said antibodies or antigen binding parts do not bind to mouse PD-L2 and human PD-L1 but bind to cyno PD-L2, preferably as determined by FACS analysis. The present invention also relates to nucleotide sequences encoding the anti-human PD-L2 antibodies, vectors and cells containing the nucleotide sequences. The antibodies and/or compositions of the invention are useful in human therapy, e.g., cancer therapy, and/or in cell-line based bioassays for determining T cell signalling.

Abstract: Embodiments of the disclosure include methods and compositions for treatment of a medical condition related to the liver, including at least viral infections and liver cancer, for example. In specific embodiments, immunotherapies are provided for delivering polynucleotides locally to the liver, wherein the polynucleotides encode particular gene products that include bispecific antibodies, including those that target certain liver antigens, for example.

Abstract: The invention relates to multispecific antibody constructs comprising Fab fragments having a particular set of mutations at the interface of the CH1 and CL domains, the mutations preventing heavy chain/light chain mispairing.

Abstract: A method for producing a dual function protein includes a biologically active protein and an FGF21 mutant protein. The method allows stable production of a target protein by effectively preventing decomposition of the target protein, and thus has a high potential for commercial usage.

Abstract: Provided herein are multispecific antibodies that selectively bind to PSMA and effector cell antigens such as CD3, pharmaceutical compositions thereof, as well as nucleic acids, and methods for making and discovering the same.

Abstract: The invention relates to the field of cell culture technology. It concerns the knockdown, using RNA interference, or gene knockout, of activating transcription factor 6 beta (ATF6B), or the combination of ceramide synthase 2 (CERS2) and TBC1 domain family member 20 (TBC1D20) proteins, which play central roles in the cellular secretion pathway. This downregulation leads to improved secretion of biopharmaceutically relevant products produced in mammalian cells. The invention specifically relates to mammalian cells having enhanced secretion of a recombinant therapeutic protein compared to a control cell, a method of producing said mammalian cell, a method for the production of a recombinant secreted therapeutic protein and the use of said mammalian cell for increasing the yield of a recombinant secreted therapeutic protein.

Abstract: The present disclosure provides antibodies or antibody fragments specific for GPVI. In particular, it relates to antibodies or antibody fragments that have combined beneficial properties and are therefore useful for the treatment or prophylaxis of GPVI related disorders or conditions, such as for example thrombotic or vascular disorders.

Abstract: Disclosed herein are inducible monovalent target-binding proteins which are activated upon protease cleavage. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are further provided.

Abstract: The present disclosure provides RNA-guided CRISPR-Cas effector proteins, nucleic acids encoding same, and compositions comprising same. The present disclosure provides ribonucleoprotein complexes comprising: an RNA-guided CRISPR-Cas effector protein of the present disclosure; and a guide RNA. The present disclosure provides methods of modifying a target nucleic acid, using an RNA-guided CRISPR-Cas effector protein of the present disclosure and a guide RNA. The present disclosure provides methods of modulating transcription of a target nucleic acid.

Abstract: The invention relates to a novel antibody and an antibody fragment that specifically bind to PD-L1 and a composition comprising the antibody or the antibody fragment. In addition, the invention relates to a nucleic acid encoding the antibody or the antibody fragment thereof, a host cell comprising the nucleic acid, and a related use. Furthermore, the invention relates to a therapeutic and diagnostic use of these antibodies and antibody fragments. Particularly, the invention relates to a combined treatment of these antibodies and antibody fragments with other therapies.

Abstract: Anti-RSV antibodies with neutralizing potency against RSV subtype A and RSV subtype B are provided, as well as methods for their identification, isolation, generation, and methods for their preparation and use are provided.

Abstract: Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.

Abstract: Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.

Abstract: The application provides anti-PD-1 monoclonal antibodies, antigen binding portions thereof, therapeutic compositions thereof and/or nucleic acid encoding the same, and their use to upregulate the function of T-cells to enhance cell-mediated immune responses in the treatment of cancer and other T-cell dysfunctional disorders.

Abstract: The present invention provides antibodies, or antigen-binding portions thereof, which specifically bind to IL-2 and reduce the affinity of IL-2 binding to IL-2R? and IL-2R?. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of autoimmune diseases, disorders or conditions and for immunosuppression, including, but not limited to, administering a complex comprising the antibody and IL-2.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The invention relates to multimers such as tetramers of polypeptides and tetramers and octamers of effector domains, such as antigen binding sites (eg, antibody or TCR binding sites that specifically bind to antigen or pMHC, or variable domains thereof) or peptides such as incretin, insulin or hormone peptides.

Abstract: A method of making an antibody in plants that binds to ricin B chain is described. The method comprises (a) introducing a nucleic acid molecule encoding a heavy chain variable region of the antibody and a nucleic acid molecule encoding a light chain variable region of the antibody into a plant or plant cell; and (b) growing the plant or plant cell to obtain a plant that expresses the antibody or antibody fragment. The disclosure also relates to anti-ricin B chain antibodies and antibody fragments as well as methods of using same in therapy and prophylaxis.

Abstract: In one aspect, methods of generating human monoclonal antibodies that specifically binds to an allergen are provided. In some embodiments, the monoclonal antibodies are generated from sequences identified from isolated single B cells from a human subject who is allergic to the allergen.

Abstract: The present invention is directed to a monoclonal antibody or an antigen-binding portion thereof having specific binding affinity to RING finger protein 4 (RNF4). The invention is further directed to use of the antibody or an antigen-binding portion thereof in detecting a RNF4-associated disease in a subject, such as cancer.

Abstract: Anti-CD47 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, and methods of producing the antibodies and using the antibodies for treating or preventing diseases such as cancer, inflammatory disease, infectious disease, atherosclerosis, cardiovascular disease, metabolic disease, radiation-induced injury, and/or autoimmune disease.

Abstract: In accordance with the present invention, CHO cells expressing a recombinant polypeptide of interest are grown in media where the amino acids, vitamins, phosphate, lipids and/or antioxidant optimization is utilized to manipulate and/or control the protein quality attributes of the polypeptides. Polypeptides expressed in accordance with the present invention may be advantageously used in the preparation of pharmaceutical compositions.

Abstract: Cell-associated secretion-enhancing fusion proteins are disclosed that comprise a target protein binding domain and a transmembrane retention domain. Co-expression in a host cell of a fusion protein and a target protein of interest that is temporarily bound by the fusion protein leads to an increased level of target protein secreted from the host cell. The fusion proteins are engineered to be retained with the producing host cell, thus eliminating a non-natural component from the extracellular media of the host cell and simplifying purification of the target protein. Nucleic acid molecules encoding such fusion proteins are also disclosed for use in expressing the fusion proteins in host cells, for use in restoring lost or diminished cell functions, and for use in treating diseases characterized by a lost or diminished cell function. Methods and compositions comprising fusion proteins of the invention are disclosed for use in enhancing the level of co-expressed target proteins secreted from host cells.

Abstract: It is provided an inhibitor of Toll-like Receptor 2 (TLR2) that specifically blocks an interaction between S1009A and Toll-like Receptor 2 (TLR2), and more particularly a humanized antibody against S100A9 protein for inhibiting and treating inflammatory conditions in a human patient. Particularly, this humanized antibody is specific for blocking the interaction between the S100A9 protein and the TLR-2 receptor.

Abstract: Methods for preparing a recombinant protein from a bacterium are provided. The method includes constructing an expression vector including two promoters. Each of the two promoters attaches a secretion signal peptide to one polypeptide of a protein. The protein attached with the two promoters and secretion signal peptides is then cloned into the expression vector to provide a recombinant expression plasmid. The recombinant expression plasmid is transformed into a host cell. A fermentation process is performed to grow the host cell and to induce an expression to synthesize polypeptides in the host cell and to transport the polypeptides to an outside of a cytoplasm of the host cell, such that the polypeptides are released in a soluble form in a growth medium of the host cell. The polypeptides are assembled into a three-dimensional structure of the protein. The protein is captured from the growth medium.

Abstract: The invention relates to an artificial nucleic acid molecule comprising an open reading frame and a 3?-UTR comprising at least one poly(A) sequence or a polyadenylation signal. The invention also relates to a method for increasing protein production from an artificial nucleic acid molecule and to the use of a 3?-UTR for a method for increasing protein production from an artificial nucleic acid molecule. Moreover, the invention concerns the use of the artificial nucleic acid molecule as a medicament, as a vaccine or in gene therapy.

Abstract: The present disclosure provides coronavirus S1-fragment specific binding moieties comprising Type II VNAR domains, VNAR antibodies, methods of using those moieties and antibodies to treat COVID-19. In some embodiments, a VNAR antibody, originally selected from a phage display library as a VNAR clone using S1fragments from the SARS-CoV-2 Wuhan strain, are also effective at specifically binding to and/or neutralizing SARS-CoV-2 and certain SARS-CoV-2 mutants.

Abstract: The present invention further relates to specific humanised monoclonal antibodies inhibiting ADAMTS13 function. The present invention relates to methods of treatment by human ADAMTS13 inhibition in circulatory assist device induced haemorrhagic complication such as a bleeding disorder, in particular, bleeding after left ventricular assist device (LVAD) implantation.

Abstract: The present invention relates to alpha-amylase variants comprising a substitution at a position corresponding to position 188 and at least one further substitution at a position corresponding to position 242 or 279 or 275 of SEQ ID NO: 1, in particular one or more combinations of substitutions selected from the group consisting of E188P+S242Y, E188P+S242F, E188P+S242H, E188P+S242W, E188P+S242P, E188P+S242I, E188P+S242T, E188P+S242L, E188P+K279W, E188P+K279Y, E188P+K279F, E188P+K279H, E188P+K279I, E188P+K279L, E188P+K279D, E188P+K279M, E188P+K279S, E188P+K279T E188P+K279N, E188P+K279Q, E188P+K279V, E188P+K279A, E188P+N275F, E188P+N275Y, E188P+N275W, and E188P+N275H, wherein the variant has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%, but less than 100% sequence identity to a parent alpha amylase selected from the group consisting of: SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO:

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a SIRPA polypeptide, e.g., a mammalian SIRPA or human SIRPA, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Abstract: The present application relates to anti-PD-L1 antibodies and their use to detect PD-L1 in a sample from a subject. In some embodiments, the subject has been treated with a therapeutic anti-PD-L1 antibody and an anti-PD-L1 described herein does not compete for binding to PD-L1 with the therapeutic anti-PD-L1 antibody. In some embodiments, the anti-PD-L1 antibody is linked to a N detectable moiety, such as a fluorophore and the anti-PD-L1 antibody is used to detect PD-L1 in a subject using flow cytometry.

Abstract: Provided herein, inter alia, are isolated, humanized antibodies that bind an extracellular domain of a human SIRP-? polypeptide. Also provided are polynucleotides, vectors, host cells, and methods of production and use related thereto.

Abstract: In one aspect, present invention provides a recombinant mutant human factor VIII having increased expression and/or secretion as compared to wild-type factor VIII. In certain embodiments, the recombinant factor VIII includes one or more amino acid substitution(s) selected from the group consisting of I86, Y105, A108, D115, Q117, F129, G132, H134, M147 and L152. In other aspects, the present invention provides FVIII encoding nucleic acids, FVIII-expression vectors, as well as methods of using the modified FVIII genes in the treatment of FVIII deficiencies, such as hemophilia A.

Abstract: Disclosed herein are antibodies that specifically bind human erythroferrone and assay methods for detecting and/or measuring human erythroferrone, analogs of human erythroferrone, and fragments thereof. Specifically, the methods comprising using an antibody as a capture reagent and an antibody as a detection reagent for detecting or measuring a detectable label of the at least one detection reagent bound to the erythroferrone polypeptide that is bound to the capture reagent. Further disclosed are the sequences of antibodies.

Abstract: The present disclosure relates to protein molecules that specifically bind to CD123, which may have at least one humanized or human CD123-binding domain. Such molecules are useful for the treatment of cancer. The protein molecule binding to CD123 may have a second binding domain that binds to another target. In one embodiment, multi-specific polypeptide molecules bind both CD123-expressing cells and the T-cell receptor complex on T-cells to induce target-dependent T-cell cytotoxicity, activation, and proliferation. The disclosure also provides pharmaceutical compositions comprising the CD123-binding polypeptide molecules, nucleic acid molecules encoding these polypeptides and methods of making these molecules.

Abstract: The present disclosure relates to, inter alia, a method of treating age-related macular degeneration (AMD) in a patient, comprising administering an effective amount of a C5 inhibitor or a C5a inhibitor.

Abstract: The present invention provides an anti-LAG-3 antibody capable of repeated administration even to animals other than rat. An anti-LAG-3 antibody comprising (a) a light chain comprising a light chain variable region containing CDR1 having the amino acid sequence of QSLLDSDGNTY (SEQ ID NO: 16), CDR2 having the amino acid sequence of SVS and CDR3 having the amino acid sequence of MQATHVPFT (SEQ ID NO: 17) and the light chain constant region of an antibody of an animal other than rat; and (b) a heavy chain comprising a heavy chain variable region containing CDR1 having the amino acid sequence of GFDFDTYP (SEQ ID NO: 18), CDR2 having the amino acid sequence of ITIKTHNYAT (SEQ ID NO: 19) and CDR3 having the amino acid sequence of NREDFDY (SEQ ID NO: 20) and the heavy chain constant region of an antibody of an animal other than rat. A pharmaceutical composition comprising the above anti-LAG-3 antibody as an active ingredient. A method for preparing the above anti-LAG-3 antibody is also provided.